Actively Recruiting
Observing the Role of Inflammation in Peripheral Artery Disease and Its Impact on Heart and Mobility Health: PANACEA-O.
Led by Cardiology Research UBC · Updated on 2026-03-30
50
Participants Needed
1
Research Sites
39 weeks
Total Duration
On this page
Sponsors
C
Cardiology Research UBC
Lead Sponsor
N
Novo Nordisk A/S
Collaborating Sponsor
AI-Summary
What this Trial Is About
This registry aims to collect detailed information about people in Canada who have Peripheral Artery Disease (PAD) and are receiving care in heart clinics while still able to walk and live in the community. Researchers want to better understand what these patients are like at the start of their care and looking at their general health, levels of inflammation in their bodies, and how well they can move and function in daily life. The results of this study will help healthcare providers better understand what PAD looks like in today's Canadian heart clinics. It will also help guide future research studies that focus on inflammation and PAD. The researchers believe that PAD patients can be routinely recruited from these clinics, and that most of these patients will have high levels of inflammation (shown by high blood CRP levels) and poor physical ability when they first join. The findings will show that there is a strong need to regularly check for PAD in heart clinics so that patients can be identified early and offered new treatments in the future and especially treatments that may help reduce inflammation.
CONDITIONS
Official Title
Observing the Role of Inflammation in Peripheral Artery Disease and Its Impact on Heart and Mobility Health: PANACEA-O.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 19 years or older
- Ability to provide informed consent before any trial-related activities
- Symptomatic PAD with intermittent claudication at Fontaine stage IIa
- Stable symptoms with ability to walk more than 200 meters without stopping for at least 90 days prior to screening
- Ankle-brachial-index (ABI) equal to or below 0.90 in the affected leg or 50% or greater stenosis in a peripheral artery confirmed by imaging or history of lower extremity revascularization
You will not qualify if you...
- Current or previous treatment with any immunomodulating agent within 90 days prior to screening
- Walking ability limited by conditions other than PAD
- Planned orthopedic surgery in the legs or other major surgery affecting walking ability known at screening
- Vascular revascularization procedure for PAD within 180 days prior to screening
- Planned arterial revascularization known at screening
- Myocardial infarction, stroke, hospitalization for unstable angina, or transient ischemic attack within 180 days prior to screening
- Heart failure classified as New York Heart Association (NYHA) class III-IV
- Signs or symptoms of critical limb ischemia such as leg gangrene, rest pain, or ischemic wounds
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Vancouver General Hospital
Vancouver, British Columbia, Canada, V5Z 1M9
Actively Recruiting
Research Team
J
Jackie Chow, BSN
CONTACT
R
Robyn Szchory, BSN
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here